Russell Investments Group Ltd. Sells 3,339 Shares of Amphastar Pharmaceuticals Inc (AMPH)

Russell Investments Group Ltd. reduced its holdings in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 4.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,127 shares of the company’s stock after selling 3,339 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.15% of Amphastar Pharmaceuticals worth $1,235,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of AMPH. Municipal Employees Retirement System of Michigan grew its holdings in shares of Amphastar Pharmaceuticals by 2.8% during the second quarter. Municipal Employees Retirement System of Michigan now owns 8,430 shares of the company’s stock worth $151,000 after buying an additional 230 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Amphastar Pharmaceuticals by 1.1% during the second quarter. The Manufacturers Life Insurance Company now owns 28,701 shares of the company’s stock worth $512,000 after buying an additional 312 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 17.7% during the second quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock worth $100,000 after buying an additional 842 shares in the last quarter. Thrivent Financial For Lutherans grew its holdings in shares of Amphastar Pharmaceuticals by 7.2% during the second quarter. Thrivent Financial For Lutherans now owns 21,610 shares of the company’s stock worth $386,000 after buying an additional 1,460 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Amphastar Pharmaceuticals by 2.8% during the second quarter. Rhumbline Advisers now owns 69,763 shares of the company’s stock worth $1,246,000 after buying an additional 1,925 shares in the last quarter. Hedge funds and other institutional investors own 44.14% of the company’s stock.

AMPH has been the subject of a number of recent research reports. BMO Capital Markets lifted their price target on shares of Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the stock a “market perform” rating in a report on Friday, November 10th. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Raymond James Financial downgraded shares of Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price target for the company. in a report on Thursday, November 9th. Needham & Company LLC lifted their price target on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, December 1st. Finally, Jefferies Group set a $19.00 target price on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, October 29th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $19.50.

Shares of Amphastar Pharmaceuticals Inc (NASDAQ AMPH) opened at $19.75 on Thursday. Amphastar Pharmaceuticals Inc has a twelve month low of $12.05 and a twelve month high of $19.95. The stock has a market cap of $890.55, a P/E ratio of 129.13 and a beta of 1.69. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.05. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The firm had revenue of $57.90 million during the quarter, compared to the consensus estimate of $57.23 million. During the same period in the previous year, the firm earned $0.14 earnings per share. Amphastar Pharmaceuticals’s revenue was down 9.8% compared to the same quarter last year. equities analysts anticipate that Amphastar Pharmaceuticals Inc will post -0.03 EPS for the current year.

In other Amphastar Pharmaceuticals news, Director Stephen B. Shohet sold 7,866 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $18.87, for a total transaction of $148,431.42. Following the transaction, the director now directly owns 31,982 shares of the company’s stock, valued at $603,500.34. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Stephen B. Shohet sold 7,862 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $18.34, for a total transaction of $144,189.08. Following the transaction, the director now directly owns 31,978 shares in the company, valued at $586,476.52. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 203,440 shares of company stock valued at $3,763,789. 11.10% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: “Russell Investments Group Ltd. Sells 3,339 Shares of Amphastar Pharmaceuticals Inc (AMPH)” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/12/28/russell-investments-group-ltd-sells-3339-shares-of-amphastar-pharmaceuticals-inc-amph.html.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH).

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

What are top analysts saying about Amphastar Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amphastar Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit